Bile duct cancer market forecast to reach $3.89 billion by 2030

The bile duct cancer market is projected to grow from $2.82 billion in 2026 to $3.89 billion by 2030, driven by rising liver disease rates, more precision oncology investment and wider use of advanced diagnostics. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Bile duct cancer remains difficult to catch early, so demand is growing for better diagnostics, staging tools and treatment options. - The market outlook points to more spending on precision oncology, immunotherapy and AI-assisted cancer detection. - Rising liver disease rates are expanding the pool of patients at risk for bile duct cancer.

What happened: - The Business Research Company said the global bile duct cancer market was valued at $2.59 billion in 2025 and is expected to reach $2.82 billion in 2026. - The company projected the market will climb to $3.89 billion by 2030, at an 8.4% CAGR. - The report covers market size, trends and a global forecast for 2026-2035. - A free sample of the report is available here. - The full report is available here.

The details: - Bile duct cancer is a rare cancer that starts in the bile ducts, which carry bile from the liver to the gallbladder and small intestine. - Many diagnoses happen at advanced stages, after symptoms such as jaundice, unexplained weight loss and abdominal pain appear. - The report links recent market growth to early-diagnosis challenges, higher rates of liver and bile duct disorders, broader chemotherapy use and growing awareness of rare cancers. - The forecast period is supported by investment in precision oncology research, wider immunotherapy use, advanced screening methods, AI-assisted cancer diagnostics and personalized treatment plans. - The report highlights rising use of targeted therapies, improved imaging, multidisciplinary care models, precision oncology expansion and earlier detection with better staging. - The report says North America held the largest share of the global market in 2025. - Asia-Pacific is expected to post the fastest growth as healthcare access improves and awareness rises in emerging economies. - The market study includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The biggest demand driver is not just cancer incidence. It is the combination of late diagnosis and more at-risk patients from liver disease. - The market shift toward AI tools and precision oncology suggests providers are looking for earlier detection and more individualized treatment paths. - The regional split shows mature markets still lead on infrastructure, while faster growth is moving toward countries building out care capacity. - The World Health Organization reported in July 2024 that global prevalence of chronic liver diseases, including non-alcoholic fatty liver disease, rose to about 30.2% from previous estimates of 26%.

What's next: - More oncology centers are likely to adopt advanced imaging, AI-assisted diagnostics and multidisciplinary care models. - Precision oncology and immunotherapy are expected to stay central to market growth through 2030. - Asia-Pacific could narrow the gap with North America if healthcare access and screening improve as projected. - The Business Research Company has added updated strategic tools in its 2026 reports, including TAM analysis, market attractiveness scoring, company scoring matrices, forecasting dashboards, hotspot infographics and updated graphics and tables.